Omeros (OMER) Revenue (2010 - 2026)

Omeros (OMER) posted Revenue of $9.9 million for Q1 2026, down 2.07% sequentially from $10.1 million in Q2 2022.

Analysis

Omeros (OMER) Revenue (2010 - 2026) Analysis & Trends

Omeros has reported Revenue for 14 years, with the latest figure at $9.9 million in Q1 2026.

Quarterly Revenue changed N/A year-over-year to $9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.0 million (up 142.99% YoY) and the FY2020 annual result came in at $73.8 million, down 33.98% from the prior year.
Revenue eased to $9.9 million in Q1 2026 per OMER's latest filing, from $10.1 million in the prior quarter.
Over five years, Revenue peaked at $10.1 million in Q2 2022 and troughed at $7.0 million in Q1 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	139.27 Bn	131.42 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	85.55 Bn	77.56 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	63.45 Bn	58.27 Bn	1.37 Bn	1.52 Bn
4	Moderna	57.73 Bn	52.59 Bn	52.00 Mn	145.00 Mn
5	Revolution Medicines	44.08 Bn	44.08 Bn	-	-
6	BeOne Medicines	39.95 Bn	34.85 Bn	1.53 Bn	1.71 Bn
7	Alnylam Pharmaceuticals	35.14 Bn	31.84 Bn	992.69 Mn	1.29 Bn
8	Royalty Pharma	28.44 Bn	27.60 Bn	-	674.14 Mn
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn	425.49 Mn
10	Omeros	1.37 Bn	1.37 Bn	27.73 Mn	28.53 Mn

Historic Data

Download Data